Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,591 recruiting studies in this area right now.
By phase
- Not applicable9,784
- Phase 24,449
- Phase 12,735
- Phase 1/Phase 21,686
- Phase 31,394
- Phase 2/Phase 3280
- Phase 4263
Top conditions
- Breast Cancer1,225
- Cancer661
- Prostate Cancer653
- Colorectal Cancer491
- Lung Cancer424
- Ovarian Cancer338
- Multiple Myeloma332
- Gastric Cancer296
- Acute Myeloid Leukemia292
- Pancreatic Cancer289
- Hepatocellular Carcinoma283
- Solid Tumor256
- Advanced Solid Tumor255
- Cervical Cancer232
- Head and Neck Cancer227
- Endometrial Cancer206
- Advanced Solid Tumors193
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center450
- Fudan University312
- Sun Yat-sen University291
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)286
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center147
- AstraZeneca134
- University Health Network, Toronto125
Where studies are running
- California1,425
- Texas638
- Arizona512
- Florida448
- Alabama420
- New York408
- Massachusetts343
- Maryland330
- New Jersey269
- Pennsylvania242
Recruiting studies20,591 total
- NCT05905315RecruitingPhase 2
Vulvar cancer treatment: chemoradiation vs chemotherapy then surgery
This Phase 2 trial compares two treatment approaches for some women with vulvar squamous cell cancer: chemoradiation first, or chemotherapy first followed by surgery. The goal is to see which strategy works better or is safer for tumors that are hard to remove without major pelvic surgery.
AmsterdamAges 18 years+ - NCT05718726Recruiting
Study of infections after spleen removal surgery
This trial looks at what happens after surgery to remove the spleen in people who also have major cancer surgery through the belly. It may help reduce or better manage serious infections after this kind of operation.
Basingstoke, HampshireAges 18–79 - NCT05715931RecruitingPhase 2
Surgery chemotherapy plus anti-HER2 and anti–immune therapy for HER2 stomach cancer
This Phase 2 trial tests adding chemotherapy plus trastuzumab and toripalimab around the time of surgery for HER2-positive, locally advanced stomach or esophagus-stomach junction cancer. It aims to shrink the cancer and reduce the chance it comes back by attacking it through more than one pathway.
Hangzhou, ZhejiangAges 18–80 - NCT05686538RecruitingPhase 2/Phase 3
Study of donor immune cells after stem cell transplant for AML/MDS
This trial tests whether infusing donor immune cells after a stem cell transplant can help treat AML or MDS. It involves donating and receiving a specific type of immune-cell infusion, with safety checks around the donor’s procedure.
CopenhagenAges 18–80 - NCT05651594RecruitingPhase 2
Propranolol with pembrolizumab and chemotherapy for esophageal cancer
This trial tests whether adding propranolol (a common blood-pressure/heart medicine) can improve outcomes when used with pembrolizumab plus standard chemotherapy. It is for people with advanced esophageal or gastroesophageal junction adenocarcinoma that cannot be removed with surgery.
Buffalo, New YorkAges 18 years+ - NCT05411523Recruiting
Spinal cord stimulation study for long-term chemotherapy nerve pain
This trial tests whether spinal cord stimulation can reduce pain and improve quality of life in people with long-lasting nerve pain from chemotherapy (CIPN). You must already have tried at least two nerve-pain medicines and still have significant pain, and you must have had a successful spinal cord stimulator test before joining.
Rochester, MinnesotaAges 18 years+ - NCT05873712RecruitingPhase 2
Zanubrutinib plus CAR-T for Richter syndrome
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
New York, New YorkAges 18 years+ - NCT05665738Recruiting
Two-visit HDR radiation to treat early prostate cancer
This study tests a radiation treatment delivered in two fractions (two sessions) as the only treatment for certain early-stage prostate cancers. It may help you avoid other treatments, like hormone therapy, depending on whether your cancer and health history fit the study.
San Francisco, CaliforniaAges 18 years+ - NCT05823311RecruitingPhase 3
Test lenvatinib and immunotherapy plus chemo for bile duct cancer
This Phase 3 study tests whether a combination of lenvatinib, an immunotherapy medicine (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) works better for advanced bile duct cancer that cannot be fully removed by surgery. It may help people live longer or control the cancer for longer.
Hangzhou, ZhejiangAges 18–75 - NCT05642897Recruiting
Mind program for women receiving breast cancer radiotherapy
This trial tests a “Mind Programme” designed to support women with breast cancer who are currently receiving radiation treatment. It may help with emotional well-being during radiotherapy, but you must meet specific health and language requirements.
CoimbraAges 18–70 - NCT05645523RecruitingEarly Phase 1
ICG dye mapping to find lymph nodes in some childhood tumors
This early study tests using a special dye (indocyanine green, or ICG) to help surgeons find the correct “sentinel” lymph nodes during surgery in children with certain suspected tumors. If successful, it may improve how doctors remove and check lymph nodes while reducing the chance of missing important areas.
Chicago, IllinoisAges Up to 20 years - NCT05909436RecruitingPhase 1/Phase 2
Study GLS-012 for advanced solid tumors
This trial tests an immunotherapy drug called GLS-012, alone and with another drug (GLS-010), in people with advanced solid cancers that have worsened despite standard treatment. It aims to see how well the treatment works and how safe it is, especially when given in different combinations.
BeijingAges 18–75 - NCT05745623RecruitingPhase 1/Phase 2
Testing an NTRK-fusion drug for advanced tumors
This Phase 1/2 study tests ICP-723, a medicine designed to treat cancers that have an NTRK gene fusion. It may help shrink tumors in people whose cancer test shows this specific genetic change and who haven’t taken an NTRK inhibitor before.
Guangzhou, GuangdongAges 2 years+ - NCT05642611RecruitingPhase 3
Cooling and compression for nerve protection during chemotherapy
This study tests whether using cooling and/or compression on the arms or legs can prevent nerve damage that can happen from certain chemotherapy drugs. If you get eligible chemo soon, this may help lower the chance of painful numbness or tingling during treatment.
Birmingham, AlabamaAges 18 years+ - NCT05451602RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with RET changes
This early-stage study tests a new drug (HEC169096) in people with advanced solid tumors that cannot be removed by surgery. It focuses on tumors with specific RET gene changes, aiming to control or shrink the cancer and improve outcomes.
GuangzhouAges 18 years+ - NCT05378087Recruiting
Compare two ways to plan treatment for cervical cancer
This study compares two staging methods—using surgery results versus imaging tests—to help doctors plan treatment for locally advanced cervical cancer. It may improve how accurately the cancer is mapped, which could affect treatment choices and outcomes.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05620017RecruitingPhase 1
Early test of an injection for advanced solid tumors
This Phase 1 study tests BAT8008 injection to see how safe it is, how well the body handles it, and how it affects the body’s drug levels. It’s for adults with advanced or metastatic solid tumors that are not responding to, or can’t be tolerated with, standard treatments.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT05584449Recruiting
After-cancer group program for young adult survivorship goals
This trial offers a structured group curriculum to help young adults after cancer treatment manage survivorship concerns and improve outcomes. You may be eligible if you finished curative cancer treatment recently and can fully join all six group meetings.
Scottsdale, ArizonaAges 18–39 - NCT05329103RecruitingPhase 1
Test drug PEEL-224 in advanced solid tumor cancers
This Phase 1 study tests PEEL-224 in people whose solid tumors are advanced and have not responded to standard treatments (or have no approved standard option). It focuses on safety and early signs of whether the drug can help shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT05403242RecruitingPhase 1/Phase 2
Study drug RC48-ADC plus S-1 for advanced HER2 stomach cancers
This Phase 1/2 study tests RC48-ADC (an antibody-drug treatment) together with S-1 (a chemotherapy medicine) in people with advanced stomach or esophagus/gastroesophageal junction cancer. It’s mainly for cancers with HER2 testing results of IHC 2+ and FISH-negative, and aims to find a safe dose and how well the treatment works as a first treatment option.
BeijingAges 18 years+ - NCT05506410Recruiting
Newly diagnosed mantle cell lymphoma study with Hanlikang and BTK drugs
This trial studies how well Hanlikang and a BTK inhibitor work for people newly diagnosed with mantle cell lymphoma. The goal is to improve lymphoma control while checking safety, since you must meet specific blood, organ, and health requirements.
Zhengzhou, HenanAges 18–90 - NCT05286138Recruiting
Cancer outcomes in people with blood disorders like thalassemia or sickle cell
This study looks at how cancers occur and what they look like in people with certain inherited blood disorders, such as beta-thalassemia, hemoglobin H disease, and sickle cell disease. It may help doctors better understand cancer patterns in these conditions so care can be improved.
CagliariAges 18–100 - NCT05388695RecruitingPhase 1
Testing dual-target CAR T cells for B-cell blood cancers
This Phase 1 study tests CAR T cells designed to attack B-cell blood cancers using two targets (CD19 and CD20/CD22). It may help people whose cancer has come back or not responded to standard treatments, but it is mainly to check safety and early effectiveness.
Wuhan, HubeiAges 18–70 - NCT05563558RecruitingPhase 2
Testing pembrolizumab plus chemotherapy for aggressive metastatic prostate cancer
This Phase 2 trial tests pembrolizumab together with carboplatin and cabazitaxel in men with aggressive, metastatic prostate cancer that has become resistant to hormone therapy. It may help shrink tumors and improve outcomes for people with hard-to-treat forms of prostate cancer.
MadridAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,591 recruiting oncology studies from the U.S. registry right now, out of 31,235 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.